The growth of digital (and social) as a channel to communicate has impacted almost every industry, including the way we communicate with healthcare professionals, patients, carers and other stakeholders in pharmaceutical marketing. The advent of COVID-19 has then further accelerated that trend.
Partnerships with Key Opinion Leaders (KOLs) have long been a cornerstone of pharma marketing, with these experts providing advice, medical guidance and acting a key channel to engage the HCP community. These KOLs may use many channels to stay active in their community, including conferences and publications as well as digital channels.
Digital Opinion Leaders (DOLs) may also fit this traditional mould of a KOL, but they will also be active within a particular digital channel, with a loyal and substantial community of peers. They will be comfortable in these channels and actively share the latest in medical information. Their substantial audience of peers gives them significant reach within the HCP community. Essentially, they sit right at the overlap between traditional KOLs and online influencers.
Partnerships with Key Opinion Leaders (KOLs) have long been a cornerstone of pharma marketing, with these experts providing advice, medical guidance and acting a key channel to engage the HCP community. These KOLs may use many channels to stay active in their community, including conferences and publications as well as digital channels.
Digital Opinion Leaders (DOLs) may also fit this traditional mould of a KOL, but they will also be active within a particular digital channel, with a loyal and substantial community of peers. They will be comfortable in these channels and actively share the latest in medical information. Their substantial audience of peers gives them significant reach within the HCP community. Essentially, they sit right at the overlap between traditional KOLs and online influencers.